Inlyta

Advanced renal cell carcinoma (RCC) after failure of prior treatment w/ sunitinib or cytokine.

Adult Initially 5 mg bd.

May be taken with or without food.

Hypersensitivity.

Discontinue use if posterior reversible encephalopathy syndrome occurs; nephrotic syndrome develops. Not to be used in patients w/ evidence of untreated brain metastasis or recent active GI bleeding. HTN; history of aneurysm, arterial & venous embolic & thrombotic events. Periodically monitor signs & symptoms of cardiac failure, GI perforation or fistula; thyroid function; Hb & haematocrit elevations; proteinuria & LFTs prior to & periodically thereafter. Discontinue use at least 24 hr prior to scheduled surgery. Not to be taken by patients w/ galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. May affect ability to drive & use machines. Not to be used in severe hepatic impairment (Child-Pugh class C). Renal & moderate hepatic impairment (Child-Pugh class B). May impair fertility. Women of childbearing potential must use effective contraception during & up to 1 wk after last dose. Not to be used during pregnancy & lactation. Childn & adolescents <18 yr.

Hypothyroidism; decreased appetite; headache, dysgeusia; HTN, haemorrhage; dyspnoea, cough, dysphonia; diarrhoea, vomiting, nausea, abdominal pain, constipation, stomatitis, dyspepsia; palmar-plantar erythrodysaesthesia, rash, dry skin; arthralgia, pain in extremity; proteinuria; fatigue, asthenia, mucosal inflammation; decreased wt. Anaemia, thrombocytopenia, polycythaemia; hyperthyroidism; dehydration, hyperkalaemia, hypercalcaemia; dizziness, tinnitus; cardiac failure events, venous & arterial embolic & thrombotic events; oropharyngeal pain; upper abdominal pain, flatulence, haemorrhoids, glossodynia, GI perforation & fistula; hyperbilirubinaemia, cholecystitis; pruritus, erythema, alopecia; myalgia; renal failure; increased lipase, ALT, amylase, AST, alkaline phosphatase, creatinine & TSH.

Increased plasma conc w/ CYP3A4/5 inhibitors eg, ketoconazole, itraconazole, clarithromycin, erythromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin; grapefruit; strong CYP1A2 & CYP2C19 inhibitors. Reduced plasma conc w/ CYP3A4/5 inducers eg, rifampicin, dexamethasone, phenytoin, carbamazepine, rifabutin, rifapentin, phenobarb, St. John's wort. Increased plasma conc of CYP1A2 substrates eg, theophylline.

Targeted Cancer Therapy

L01EK01 - axitinib ; Belongs to the class of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors. Used in the treatment of cancer.

B